Micro-Coring® for the Treatment of Skin Laxity of the Knees

Inclusion Criteria: * Male or female age 22 to 70 * With lax skin over one or both knees, physician discretion * Able to provide written informed consent, understand and willing to comply with all study related procedures and follow-up visits * Fitzpatrick Skin Type I to VI as evaluated by the Investigator Exclusion Criteria: * Pregnant women or nursing mothers * Body mass index \> 30 · Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area * Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine * Patients with a history or presence of any clinically significant bleeding disorder * Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus * Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection) * Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin \> 150 mg/day, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days * Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area * Patients with have undergone surgery of the treatment area within last twelve (12) months, or have any scars less than twelve (12) months old in the treatment area * Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months * During the study time frame, unwilling to refrain from receiving these following aesthetic treatments within the same body region: toxin, filler, any skin resurfacing (laser, RF, ultrasound, microneedling, etc.); * Are currently enrolled in, or have overlapping participation in, another clinical trial outside of Cytrellis that includes treatment to the study area. * Unwilling to have photography taken for the study purpose * Any physical or psychological factors, in the judgment of the study investigator, may prevent subject from adhering to the study requirement correctly. * History of keloid formation or hypertrophic scarring * Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment and for the duration of the study